BofA lowered the firm’s price target on Thermo Fisher (TMO) to $545 from $680 and keeps a Buy rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especially around China, the analyst tells investors in a preview for the group.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher price target lowered to $475 from $620 at Barclays
- Thermo Fisher price target lowered to $651 from $694 at RBC Capital
- Honeywell elects Stephen Williamson to board of directors
- Kroger, Thermo Fisher, AST SpaceMobile, Southern Co, and Prospect Capital: Insider Moves Revealed!
- Thermo Fisher price target lowered to $570 from $650 at Citi